Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Carney ComplexChondrosarcomaGastrointestinal Stromal TumorParaganglioma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Linsitinib

Given PO

OTHER

Pharmacological Study

Correlative studies

Trial Locations (8)

19111

Fox Chase Cancer Center, Philadelphia

20892

National Institutes of Health Clinical Center, Bethesda

48106

Sarcoma Alliance for Research Through Collaboration, Ann Arbor

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

94304

Stanford Cancer Institute, Palo Alto

97239

Oregon Health and Science University, Portland

02115

Dana-Farber/Harvard Cancer Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01560260 - Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors | Biotech Hunter | Biotech Hunter